FDA PMA FDA Class 3 Approved 🇺🇸 United States

Hybrid Stent Graft, Thoracic Aortic Lesion Treatment

PMA: P210006 · Supplement: S010 · Decision Mar 28, 2025
Classifications
1
FEI Numbers
3
Registration Numbers
3

Basic Information

Device Name
Hybrid Stent Graft, Thoracic Aortic Lesion Treatment
Trade Name
Thoraflex™ Hybrid
PMA Number
P210006
Supplement Number
S010
Device Class
FDA Class 3
Product Code
QSK
Generic Name
Hybrid stent graft, thoracic aortic lesion treatment
Medical Specialty
Unknown
Advisory Committee
Cardiovascular
Decision
Approved
Decision Code
APPR
Decision Date
March 28, 2025
Date Received
July 10, 2024
Supplement Type
Normal 180 Day Track
Supplement Reason
Labeling Change - Indications/instructions/shelf life/tradename
Expedited Review
N

Advisory Committee Statement

approval for a change in the supplier of the bovine gelatin used to impregnate the grafts, implementation of a new sterilization suite, delivery system material changes, shelf-life updates, and other manufacturing changes.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
QSK Hybrid Stent Graft, Thoracic Aortic Lesion Treatment